Wedbush Keeps a Buy Rating on Liquidia Technologies (LQDA)

By Austin Angelo

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Liquidia Technologies (LQDAResearch Report), with a price target of $37.00. The company’s shares closed last Monday at $6.07.

According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 0.4% and a 45.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Liquidia Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $34.50.

See today’s analyst top recommended stocks >>

Based on Liquidia Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.42 million. In comparison, last year the company had a GAAP net loss of $9.69 million.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LQDA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing.